ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.
ERS Genomics and IRBM sign CRISPR/Cas9 license agreement
- Post author:
- Post published:May 21, 2024
- Post category:uncategorized